Markku Tapani Jalkanen

Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland.

Inveni Capital Oy is a venture capital investment firm with offices in Helsinki and Munich. The Finnish-German firm was founded in 2007. Their investors include the Finnish Industry Investment Ltd. as largest single investor, along with other private investors and funds as well as the University of Helsinki.

Medeia Therapeutics Oy operates a biotechnology company which discovers and develops new therapeutic approaches for diseases with unmet medical needs. It focuses areas which include the discovery, preclinical research and early development of novel therapeutics. The company’s research and development programs develops small molecules for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases. Medeia Therapeutics was founded by Jari Eerik Koistinaho in 2006 and is headquartered in Kuopio, Finland.^ ^

Lx Therapies Oy provides drug discovery solutions for cancer treatment. It focused on developing gene mediated therapies for the prevention and treatment of diseases of lymphatic vasculature. Its therapies are used for the treatment of breast cancer related lymphoedema. The company was founded in 2008 and is headquartered in Helsinki, Finland.

Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany.